Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to... see more

TSXV:SBM - Post Discussion

Sirona Biochem Corp > Bexacat is on the market - and Sirona again too late
View:
Post by SironaInvestor on Dec 14, 2022 1:20pm

Bexacat is on the market - and Sirona again too late

https://www.reuters.com/business/healthcare-pharmaceuticals/fda-approves-first-oral-treatment-cats-with-type-diabetes-2022-12-08/

Guys, this announcement again is a testament of all the missing timelines from Sirona in the past. Promoting to be very close to announce a step changing deal for pet diabetes and competition just signed a wonderful deal!!

Amazing stuff, Elanco!! Our treatment will come soon to the market, probably with the name SiroCat !! :-)
Comment by Turtle4 on Dec 14, 2022 1:50pm
Other pharma companies dont even wait after Christmas Holidays? Interesting...
Comment by str8goods4achg on Dec 14, 2022 2:22pm
Good find and iinteresting! I hope our molecule doesn't have the same risk profile as Bexacat. Not sure I'd want to give it to my cat.  Maybe this will help accelerate negotiations??
Comment by forhandlaren on Dec 14, 2022 5:05pm
Elanco where in talks with Sirona, maybe they prioritized being early on the market over safety. Safety is one if the most valuable properties that Sirona always claims, so there is a good chance that our compound is better.
Comment by MirrorWorldMan on Dec 14, 2022 9:56pm
Its an SGLT2 with an initial phase 1 study done by Wannabang who had proprietarized the data. Safety data is nonexistent with WannabangSironaflozin. My guess is Howie lost the pet deal, hard to say when he has become a mute. 
Comment by SleepyHoward on Dec 15, 2022 7:52am
Where was the problem 2 years ago when the great ceo told us we will see tge petdeal soon. Soon is now more than 2 years and we still waiting for a deal.  How can we trust a ceo like him? 
Comment by navajojoe on Dec 15, 2022 8:57am
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse